Global Congenital Heart Disease Association

Core programs

Five flagship programs. One coordinated ecosystem.

From the virtual summits to the registry initiative, every program is designed to remove friction between great congenital ideas and the patients they could reach.

Global Congenital Innovation Summits

The flagship convening: cardiologists, ACHD specialists, surgeons, medtech founders, AI companies, regulators, investors, and hospital procurement leaders.

Industry Membership Program

Startup, corporate, clinical, academic, strategic partner and investor tiers — with networking, speaking opportunities, regulatory briefings, collaboration access and investor introductions.

Market Access Council

Patient journeys, health economics, and commercialization support for your innovation.

Innovation Accelerator

Clinical advisory access, pilot project facilitation, KOL matchmaking, commercialization mentorship, grant collaboration and venture readiness support.

Congenital Innovation Registry

Shared outcomes registries, real-world evidence databases, multi-center frameworks, AI training datasets and longitudinal outcome tracking — a strategic long-term differentiator.

Industry Intelligence

Market reports, regulatory briefings and quarterly insights mapping the global congenital cardiovascular technology landscape.

Phased rollout

A 24-month operational roadmap.

  1. Phase 01
    Months 1–6

    Foundational alliance

    Founding advisory board, brand identity, stakeholder outreach, and founding members.

  2. Phase 02
    Months 6–18

    Market activation

    Inaugural projects funded, working groups, regulatory roundtables, industry insights, and investor engagement.

  3. Phase 03
    Years 2–5

    Ecosystem leadership

    Registry initiatives, policy influence, global expansion, accreditation, standards and research programs.